IMMUNOLOGY2026™ Conference Recordings For Attendees-Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles (BEACON) for Mucosal Vaccination Against Genital Herpes

Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles (BEACON) for Mucosal Vaccination Against Genital Herpes

Back to course

Video Transcription

Video Summary

Researchers developed BEACON, a mucosal adjuvant for genital herpes vaccination, to improve immune responses in the female reproductive tract. By electrostatically combining the TLR9 agonist CpG with chemokines, BEACON targets antigen-presenting cells, reduces neutrophil-driven inflammation, and helps recruit and retain CD8 tissue-resident memory T cells. In mice, vaginal boosting with BEACON plus glycoprotein D generated stronger local antibodies, better long-term survival, and reduced latent infection in dorsal root ganglia compared with intramuscular boosting. The work suggests that local mucosal immunity, especially coordinated B cells and resident CD8 T cells, is key for effective HSV protection.

Meta Tag

Date April 19, 2026 10:00 AM - 10:15 AM

Room 102

Session Innovations in Vaccine Adjuvants and Immune Modulation

Speaker Sachin Bhagchandani

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

BEACON mucosal adjuvant

genital herpes vaccine

mucosal immunity

CD8 tissue-resident memory T cells

CpG chemokine adjuvant

April 19, 2026 10:00 AM - 10:15 AM

102

Innovations in Vaccine Adjuvants and Immune Modulation

Sachin Bhagchandani

Vaccines and Immunotherapy (VAC)

2026